Results 171 to 180 of about 1,253,602 (318)

Second Primary Cancer After Bladder Cancer: A Comprehensive Analysis of a National Cancer Registry. [PDF]

Cancer Med
Buchler T, Pehalova Kusova L, Pirshtuk A, Muzik J, Babjuk M, Dusek L.   +5 more
europepmc   +1 more source

Second neoplasms after cancers of unknown primary [PDF]

, 2017
Blanc-Moya, R., La Vecchia, C., Levi, F., Maspoli-Conconi, M., Randimbison, L.   +4 more
core  

Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment [PDF]

, 2006

core   +1 more source

Causes of adult deaths in developing countries : a review of data and methods [PDF]

Relatively little attention has been paid to the problem of premature adult mortality in developing countries, despite high levels of mortality in many countries - and despite the potentially severe social and economic consequences of adult deaths ...
Hayes, Richard, Lockett, Geraldine, Mertens, Thierry, Rodrigues, Laura   +3 more
core  

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Subsequent primary and secondary neoplasms in childhood cancer survivors. [PDF]

Pol J Radiol
Bekiesińska-Figatowska M, Bilska K, Szkudlińska-Pawlak S, Klepacka T, Raciborska A, Koch I, Michalak E.   +6 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Induction of mammary neoplasms in the SPrague-Dawley rat by 430 keV neutrons and X-rays [PDF]

, 1980
Chmelevsky, D., Kellerer, Albrecht M., Shellabarger, C. J.   +2 more
core   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source